LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam

Bulletin Express

03/06

Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.

The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.

Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1148646401"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148646401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148646401?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148646401","market":"us","top_or_hot":-1,"title":"LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.</p>\n<p>The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.</p>\n<p>Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-06 19:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.</p>\n<p>The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.</p>\n<p>Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"麗珠醫藥","start_time":0,"source_url":"","article_id":"1148646401","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148646401","pubTimestamp":1772796162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药[01513]宣布越南自愿公开要约收购获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.\nThe company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.\nLivzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}